Biologics manufacturing complexity has made reliance on contract development and manufacturing organizations, commonly known as CDMOs, the default operating model for most companies without their own large-scale biologics production infrastructure, and this reliance carries risk considerations that receive less attention than the strategic and clinical decisions that dominate most pharma coverage.
Capacity constraints at leading CDMOs have periodically created real bottlenecks for companies with approved or soon-to-be-approved biologics, since building new large-scale bioreactor capacity takes years, and a CDMO’s existing capacity commitments to other clients can directly limit how quickly a company can scale production to meet demand for a newly launched or rapidly growing product.
Technology transfer, moving a manufacturing process from development scale to commercial scale or between different CDMO facilities, is a technically demanding undertaking where even minor process variations can affect product quality in ways that require additional regulatory review, and companies that underestimate the time and validation work required for technology transfer sometimes face unexpected launch delays as a result.
Single-source manufacturing dependency represents a specific supply chain vulnerability that has drawn increased regulatory and investor attention, since a company relying on a single CDMO facility for a commercial biologic faces meaningful business continuity risk from any disruption at that site, whether from equipment failure, contamination events, or broader facility-level quality issues.
Dual-sourcing strategies, qualifying a second manufacturing site or CDMO partner for the same product, have become increasingly common risk mitigation practice for commercially significant biologics, though the additional regulatory filings and validation work required to qualify a second manufacturing source represent a real cost that companies weigh against the supply security benefit.
News and analysis tracking CDMO capacity trends and specific manufacturing-related delays or disruptions across the industry, such as the reporting from The Pharma Vanguard, gives companies planning their own manufacturing strategy a more current view of where capacity constraints and single-source risks are actually concentrated.
